Please login to the form below

Not currently logged in
Email:
Password:

epigenetics

This page shows the latest epigenetics news and features for those working in and with pharma, biotech and healthcare.

GSK: we won’t be splitting up any time soon

GSK: we won’t be splitting up any time soon

Particularly in the spotlight is oncology, where GSK has cell therapy candidates, epigenetic modulators and antibodies targeting immune cells.

Latest news

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Deal Watch November 2016 Deal Watch November 2016

    licence, collaboration. 207.5. Proterosos biostructures/ Merck &Co (MSD). second collaboration to develop small molecules against an additional epigenetic target for various cancers.

  • Deal Watch January 2016 Deal Watch January 2016

    Tensha has developed an epigenetic technology that disrupts bromodomain and extra terminal domain (BET) proteins in order to develop potential treatments for cancer. ... 535. Rodin/ Biogen. Collaboration. Multi-year neuronal epigenetics research

  • Deal Watch October 2015 Deal Watch October 2015

    Proteros' epigenetics technology and structure guided discovery platform for oncology targets (discovery).

  • Pharma deals in August 2015 Pharma deals in August 2015

    This situation occurred when Genentech/Roche elected not to go further with their option to acquire the epigenetics drug discovery company, Constellation Pharmaceuticals.

  • Pharma deals in April 2015 Pharma deals in April 2015

    Resminostat has an innovative epigenetic mechanism of action that potentially enables the compound to be deployed as a novel, targeted tumour therapy Menarini is paying $102m (95m) in upfront fees and

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Professor Thomas Cech joins Storm Therapeutics Professor Thomas Cech joins Storm Therapeutics

    mature into a world leading therapeutics company targeting RNA epigenetic modulation.”.

  • Storm Therapeutics bolsters its team Storm Therapeutics bolsters its team

    As a clinician-scientist at the University of Melbourne, Professor Dawson has experience in epigenetics having spent several years researching epigenetic regulation of leukaemia stem cells. ... Keith Blundy, chief executive officer of Storm Therapeutics,

  • Storm Therapeutics strengthens its board Storm Therapeutics strengthens its board

    RNA epigenetic modulation is an exciting area of science with real potential to deliver new targeted cancer therapies. ... We look forward to Paul’s input on development and positioning of Storm’s emerging RNA epigenetics platform and programmes.”.

  • Rubius Therapeutics strengthens senior team Rubius Therapeutics strengthens senior team

    He most recently served as the senior vice president and head of the cancer epigenetics department at GlaxoSmithKline, where he was responsible for overall strategy, as well as identification and validation ... of new epigenetic targets and advancing

  • Paul Stockdale joins Oxford BioDynamics as CFO Paul Stockdale joins Oxford BioDynamics as CFO

    A spin-out from Oxford University, Oxford BioDynamics focuses on the discovery and development of epigenetic biomarkers based on regulatory genome architecture.

More from appointments
Approximately 0 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics